Strategies Adopted by Innovator Companies in Response to Biosimilars Competition

Posted 10 April 2017 By Charu Manaktala, MD, MBBS, Raymond A. Huml, MS, DVM, RAC, Nigel Rulewski, MD

placeholder+image This article examines key strategies being adopted by the innovator companies and discusses the impact these strategies are likely to have on the future market for biosimilars.

Share this article:

Categories: Biologics and biotechnology, Government affairs, Regulatory strategy, Submission and registration, Features, US, Europe, FDA, EMA

Tags: Biosimilars, Intellectual Property, Litigation, Patent Extension

Regulatory Exchange: Latest Updates From the Community